Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum.
Lenvatinib
Mediastinal carcinoma
Poorly differentiated carcinoma
Thymic carcinoma
Undifferentiated carcinoma
Weekdays-off strategy
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
04
2021
revised:
02
07
2021
accepted:
08
07
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
We describe a Case of a 74-year-old Japanese man with poorly differentiated carcinoma of the anterior mediastinum. The patient underwent anterior mediastinal tumor resection through median sternotomy. The tumor, 7.0 × 5.0 cm, had invaded surrounding tissues (pericardium, right lung, right and left brachiocephalic veins, and superior vena cava). Complete resection of the tumor was not performed. One month after the operation, the patient developed multiple pulmonary metastases, right pleural dissemination, and carcinomatous pleurisy. He was treated with lenvatinib, a novel multi-kinase inhibitor, to which the metastasis responded favorably. This case reports for the first time the clinical usefulness of lenvatinib for poorly differentiated carcinoma of the anterior mediastinum. Management of side effects by several methods, including suspending use of medication on weekends (called a weekends-off strategy), is another strong argument to continue lenvatinib administration.
Identifiants
pubmed: 34401310
doi: 10.1016/j.rmcr.2021.101477
pii: S2213-0071(21)00139-8
pmc: PMC8349103
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101477Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
All authors of the manuscript declare that there are no conflicts of interest.
Références
Lung Cancer. 2016 Sep;99:131-6
pubmed: 27565928
Tohoku J Exp Med. 2017;242(2):137-142
pubmed: 28626164
Expert Rev Anticancer Ther. 2014 Sep;14(9):1063-73
pubmed: 24927771
Anticancer Res. 2016 Jun;36(6):2939-44
pubmed: 27272808
Lancet Oncol. 2020 Jun;21(6):843-850
pubmed: 32502444
Med Oncol. 2013;30(3):676
pubmed: 23925664
Expert Opin Drug Saf. 2018 Nov;17(11):1095-1105
pubmed: 30264594
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Oncol Lett. 2017 Sep;14(3):3657-3662
pubmed: 28927127
Cancer Treat Rev. 2019 Jul;77:20-28
pubmed: 31195212
Cancers (Basel). 2020 Apr 19;12(4):
pubmed: 32325921
Cancer Immunol Immunother. 1999 Oct;48(7):396-400
pubmed: 10501853
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S102-9
pubmed: 25396306
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266